tbuckley/cabot-search huggingface dataset:
THE RELATIONSHIP BETWEEN PERICARDIAL ADIPOSE TISSUE VOLUME, ATHEROSCLEROTIC PLAQUE TYPE AND CARDIOVASCULAR RISK: A HIGH RISK PLAQUE BIOIMAGE SUB-STUDY
Authors: Naeema Ginwala-Hasan, Francis Joshi, Jason Tarkin, Samantha Sartori, Mario Garcia, Usman Baber, Roxana Mehran, Pieter Muntendam, Valentin Fuster, Zahi Fayad, James Rudd
Journal: Journal of the American College of Cardiology (2017)
SAFETY PROFILES OF PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES: AN ANALYSIS OF THE FOOD AND DRUG ADMINISTRATION MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE DATABASE FROM 2009 – 2016
Authors: Mohammad-Ali Jazayeri, Venkat Lakshmi Kishan Vuddanda, Valay Parikh, Madhav Lavu, M. Rizwan Afzal, Mohit Turagam, Sudharani Bommana, Donita Atkins, Luigi Di Biase, Andrea Natale, Saibal Kar, Vijay Swarup, Madhu Reddy, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2017)
Phase II study of weekly docetaxel in combination with capecitabine (C) in advanced gastric (AGA) and gastro-esophageal adenocarcionma (AGEA)
Authors: A. Hantel, S. Lo, A. Khorana, M. Javle, J. Hwang, H. Wang, S. Simon, T. Crandall, M. Shayne, R. K. Ramanathan
Journal: Journal of Clinical Oncology (2007)

15139 Background: Chemotherapy regimens for AGA and AGEA have shown considerable toxicity and most require continuous IV administration. Both D and C are active agents in AGA. D upregulates thymidine phosphorylase, the enzyme which catalyzes the conversion of C to 5-FU, with preclinical evidence of synergy for the combination. A phase I study of D and C showed acceptable tolerability and activity in patients (pts) with AGA (Ramanathan et al., 2005). This multi-institutional phase II trial evaluates the combination of D and C in 1 st or 2nd line treatment of AGA and AGEA. Methods: Pts with AGA/AGEA who received ≤ 1 prior chemotherapy regimen were eligible. D 30 mg/m 2 on d 1, 8 and C 825 mg/ m 2 BID were administered on days 1–14 of a 21 day cycle. The one stage study design had an accrual goal of 40 pts. The primary endpoint was to detect a 50% improvement in median survival in previously untreated pts to 10 months (mo), by one-sided log-rank test at level a = 0.05. Results: Enrollment is complete with 40 pts, all are evaluable for response and toxicity. Pt characteristics: 79% male; 94% with ECOG performance status 0/1; median age 60 yrs (34–84), 32 pts (80%) were previously untreated. Overall response rate is 25% with 1CR and 9 PR. The projected median time to progression (TTP) and survival are 6.2 and 7.8 mo respectively. Dose modifications were required in 9%. Median cycles administered 4 (range 1–10). Grade 3/4 adverse events include: diarrhea (13%), hand-foot syndrome (13%), dehydration (6%), abd pain, anorexia, fatigue, febrile neutropenia, gastric ulcer, hyperglycemia, vertigo, and vomiting (3% each). Conclusion: The combination of D and C is well tolerated and active. The preliminary TTP (6.2 mo) and survival (7.8 mo) compare favorably with published regimens for 1st line therapy, but did not meet study endpoint. The combination of D and C is an easily administered outpatient regimen for AGA and AGEA and may be worthy of further investigation with a targeted agent. (Funded by Sanofi-Aventis and Roche Pharmaceuticals). No significant financial relationships to disclose.
Defining the role of patient navigators for men with an abnormal prostate cancer screening test result in an urban setting
Authors: S. Hamer, N. J. Nonzee, M. A. Simon, D. Liu, J. M. McKoy, P. J. Byer, J. Feinglass, A. Rademaker, E. A. Calhoun, C. L. Bennett
Journal: Journal of Clinical Oncology (2009)

5120 Background: Though several navigation programs have aimed to reduce cancer health disparities, few have evaluated the role of patients’ race/ethnicity on patient navigator activities. We report preliminary data on types of encounters and actions taken to prevent delays in prostate cancer diagnosis or treatment for 82 veterans enrolled in the NCI-funded Patient Navigation Research Program in Chicago. Methods: Male lay patient navigators and a social worker recorded encounter types, perceived or patient-identified barriers, and actions taken to prevent or resolve patient barriers to follow-up after identification of an abnormal finding for prostate cancer. Results: Of our study participants, half were African-American, 57% had an annual income of less than $30,000, 68% were unemployed, 43% were married, and the mean age was 66 years old. The most common type of patient navigator encounters included phone calls with the patient and in-person visits at the hospital, 64% and 32% respectively. Two-thirds of encounters on behalf of the patient lasted less than 15 minutes. Almost all patient navigator actions resulted from proactive case management. The most common navigator actions taken were providing support, making referrals to health providers or community resources, and verifying appointments, 32%, 29%, and 15%, respectively. There was a significant difference between African-American versus White patients with respect to type of encounter and length of encounters (p=0.002 and &lt;0.0001, respectively) but not actions taken. Conclusions: Patient navigator activity for our study thus far largely consisted of proactive management of patient- and system-related barriers as opposed to reactive response to patient-identified barriers. Future navigation programs should consider tailoring gender- and culturally-matched interventions for their patients. [Table: see text] No significant financial relationships to disclose.
OMEGA-3 POLYUNSATURATED FATTY ACIDS MAY FAVORABLY AFFECT INFLAMMATORY BIOMARKERS &amp; NOVEL INDICES OF LEFT VENTRICLE FUNCTION IN PATIENTS WITH HEART FAILURE
Authors: Dimitrios Karlis, Evangelos Oikonomou, Theodoros Zografos, Gerasimos Siasos, Christine Chrysohoou, Stela Brili, George Lazaros, Sotirios Tsalamandris, Georgia Vogiatzi, Angelos Papanikolaou, Alexios Antonopoulos, Georgios Georgiopoulos, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2017)
TRENDS IN UTILIZATION OF INPATIENT PALLIATIVE CARE SERVICES AND RACIAL DISPARITY OF DISPOSITION TO HOSPICE CARE AMONG PATIENTS WITH HEART FAILURE IN THE UNITED STATES BETWEEN 2003 AND 2012
Authors: Kasra Moazzami, Elena Dolmatova, James Maher, Pallavi Solanki, Marc Klapholz, Alfonso Waller
Journal: Journal of the American College of Cardiology (2017)
TRENDS AND OUTCOMES IN DIALYSIS REQUIRING ACUTE KIDNEY INJURY AFTER AORTIC VALVE REPLACEMENT INSIGHT FROM THE NATIONWIDE INPATIENT SAMPLE
Authors: Sami Aljohani, Fahad Alqahtani, Ahmed Almustafa, Khaled Boobes, Mohammad Akram Kawsara, Chalak Berzingi, Mohamad Alkhouli
Journal: Journal of the American College of Cardiology (2017)
Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.
Authors: Lars Bastholt, Marcia S. Brose, Barbara Jarzab, Martin Schlumberger, Salvatore Siena, Christelle De La Fouchardiere, Ralf Paschke, Hari Anant Deshpande, Yuankai Shi, Rossella Elisei, Ming Gao, Lin Li, Klaas Prins, Helen Walker, David Y. Mitchell, John T. Lettieri, Istvan Molnar, Christian Kappeler, Carol Elaine Pena
Journal: Journal of Clinical Oncology (2014)

6061^ Background: The recently reported phase III DECISION trial in patients with RAI-rDTC demonstrated a significant improvement in progression free survival (PFS) associated with sorafenib treatment. The purpose of this exploratory analysis was to evaluate sorafenib pharmacokinetics (PK) in RAI-rDTC and to examine the relationship between exposure and both PFS and adverse events (AEs). Methods: In DECISION, patients with locally advanced/metastatic RAI-rDTC who progressed in the prior 14 months were randomized to sorafenib 400 mg bid po or placebo. Plasma was collected on Cycle 2 Day 1 (steady state) and sorafenib concentrations measured using LC-MS/MS. Sorafenib AUC(0-12),ss were estimated using a population PK model developed from 10 sorafenib phase I-III trials, including DECISION. Results: Plasma samples from 156 patients randomized to sorafenib were valid for the analysis. Sorafenib mean AUC(0-12),ss (95.7 mg*h/L) was 103% higher in DTC compared to RCC and HCC, although the ranges of AUCs were overlapping. No specific mechanism for the elevated sorafenib levels has been determined. Analyses of sorafenib AUC vs. PFS were not significant, although patients with the highest exposure (Quartile 4) had a numerically longer median PFS (509 days [95%CI: 283-623 days]) than those in the low (Q1) or medium (Q2+Q3) exposure groups (median PFS 305 days [95%CI: 162-448 days] and 293 days [95%CI: 231-451 days], respectively). There was no correlation between sorafenib AUC and incidence or severity of AEs (e.g. any AE, any SAE, any drug-related AE, hypertension, diarrhea, and hand-foot skin reaction). Conclusions: Sorafenib exposure was higher in DTC patients compared to patients with RCC and HCC. There was no apparent correlation between sorafenib exposure and PFS or AEs in DTC patients. This analysis is limited by the small number of subjects in each exposure subgroup and the single measurement of sorafenib AUC on Cycle 2-Day1. Clinical trial information: NCT 00895674.
Erratum: Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells
Authors: A Dar, A Schajnovitz, K Lapid, A Kalinkovich, T Itkin, A Ludin, W-M Kao, M Battista, M Tesio, O Kollet, N N Cohen, R Margalit, E C Buss, F Baleux, S Oishi, N Fujii, A Larochelle, C E Dunbar, H E Broxmeyer, P S Frenette, T Lapidot
Journal: Leukemia (2011)
Ewing tumors of the chest wall: Local control and long-term outcomes
Authors: D. J. Indelicato, S. R. Keole, A. H. Shahlaee, C. G. Morris, C. P. Gibbs, M. T. Scarborough, S. Islam, R. B. Marcus
Journal: Journal of Clinical Oncology (2009)

e21501 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy. Methods: We reviewed our experience from 1980 and 2008 including 31 patients (pts). Pts characteristics: median age 41 (19–80 y), male/female 19/12; symptoms at diagnosis: dyspnoea (42%), chest and shoulder pain (39%), cough (35%), hemophtoae (13%), discomfort (10%). 4 pts had a previous history of mediastinal radiation for Hodgkin's and non-Hodgkin's linfomas. 5 mediastinal tumours were located as follows: 2 in anterior part, 1 in posterior and 2 in the middle (sarcomas of the heart). 26 lung sarcomas presented as a singular mass in 23 cases and as a metastatic disease in 3. Results: In 20/31 cases the tumour was immediately resected (3 mediastinal masses and 17 lung sarcomas). In 8/31 cases only biopsy was possible. FNA was done in 25 pts. Neoadjuvant chemotherapy was performed in 4 cases (3 resected). Resection was complete in 11/23 cases and in 12/23 incomplete. The histology were: peripheral nerve tumour 7, leiomyosarcoma 4, MFH 2, fibrosarcoma 2, liposarcoma 1, angiosarcoma 2, undifferentiated sarcoma 1, solitary fibrous tumour 2, rhabdomyosarcoma 2, synovialsarcoma 2, pulmonary artery sarcoma 1, pleuropolmonary blastoma 1, malignant hemangiopericytoma 1, mixoid chondrosarcoma 1, ectopic osteosarcoma 1, aggressive fibromatosis 1. Only 4 pts received neoadjuvant chemotherapy, 11 adjuvant CT, 5 exclusive CT + RT for inoperable disease. Radiotherapy was completed in 26 pts (21 adjuvant). Local relapse or metastatic progression were recorded in 16/23 pts and 12 received one or more lines of palliative CT. Data about survival are disposable only for the more recently recorded pts (1998–2008: 17 pts). Of these only 8 are alive (2 with disease). Volume of disease, complete resection and grading are the dominant prognostic factors. Conclusions: Primary sarcomas of the lungs and mediastinum have a very severe prognosis. Surgical resection is the fundamental therapy, but in the future the role of neoadjuvant CT will increase. No significant financial relationships to disclose.
Metabolic reprogramming in cancer cells, consequences on pH and tumour progression: Integrated therapeutic perspectives with dietary lipids as adjuvant to anticancer treatment
Authors: Jean-François Dumas, Lucie Brisson, Stéphan Chevalier, Karine Mahéo, Gaëlle Fromont, Driffa Moussata, Pierre Besson, Sébastien Roger
Journal: Seminars in Cancer Biology (2017)
SUCCESS RATES BY ABLATION LESION SET OF CATHETER ABLATION FOR PAROXYSMAL ATRIAL FIBRILLATION: FINDINGS FROM THE SMASH-AF META-ANALYSIS STUDY COHORT
Authors: Andrew Cluckey, Fahd Yunus, George Leef, Mariam Askari, Ewoud Schuit, Paul Heidenreich, Mintu Turakhia, Alexander Perino
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF DEMOGRAPHICS AND SOCIOECONOMIC STATUS ON MODE OF TRANSPORTATION AND TIME TO PRESENTATION IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION
Authors: Andrew Stewart, Tigran Khachatryan, David Hamilton, Jonathan Evans, Daniel Amponsah, Eric Suh, Kenneth Jutzy, Islam Abudayyeh, Anthony Hilliard
Journal: Journal of the American College of Cardiology (2017)
AN IGNORED BUT NOT UNUSUAL COMPLICATION OF SEVERE PULMONARY HYPERTENSION — OSTIAL COMPRESSION OF LEFT MAIN CORONARY ARTERY BY ANEURYSMAL PULMONARY ARTERY: INSIGHTS FROM EUPHRATES STUDY
Authors: Ozgur Yasar Akbal, Cihangir Kaymaz, Fatih Yilmaz, Ibrahim Halil Tanboga, Aykun Hakgor, Canan Elif Yildiz, Hacer Ceren Tokgoz, Sevim Turkday, Durmus Demir, Seda Tanyeri, Nihal Ozdemir
Journal: Journal of the American College of Cardiology (2017)
Induction of Recipient Cell-Specific Donor T Cell Anergy by UV-C-Irradiated Recipient Immature Monocyte-Derived Dendritic Cells.
Authors: Nozomi Tochiki, Miwako Narita, Zhiyin Zheng, Chengfang Lu, Norihiro Watanabe, Anri Saitoh, Noriyuki Satoh, Tatsuo Furukawa, Ken Toba, Yoshifusa Aizawa, Masuhiro Takahashi
Journal: Blood (2007)
Diagnostic optique des polypes colorectaux grâce au système Lasereo (Blue Laser Imaging, Fujifilm) en utilisant les classifications de NICE, Sano et WASP
Authors: S Ribiere, J Dreanic, M Barret, M Camus, M Dior, B Brieau, S Leblanc, F Prat, R Coriat, S Chaussade
Journal: Endoscopy (2017)

L'objectif de notre travail était d'évaluer les performances du diagnostic optique des polypes colorectaux à l'aide d'une nouvelle technique de chromoendoscopie électronique, le Blue Laser Imaging (BLI) en s'aidant des différentes classifications NICE, Sano et WASP.
CONSENTIMIENTO INFORMADO (CI) EN ENDOSCOPIA DIGESTIVA: DE LA LEY A LA PRÁCTICA CLÍNICA
Authors: M Navarro Llavat, A Bargalló García, D Barquero Declara, F Baños, O García-Bosch, M Martín-Llahí, A Cárdenas, A Ferreras, A Mata, A Blasco
Journal: Endoscopy (2015)

La información al paciente es un derecho que éste tiene, y una obligación ética y legal. En los procedimientos diagnósticos y terapéuticos invasivos, el consentimiento debe obtenerse después de que el paciente reciba una información adecuada verbal y por escrito del mismo, sus beneficios, complicaciones y alternativas. Esta información debe proporcionarse de forma oportuna antes del procedimiento.
PHARMACOLOGICAL TREATMENT ALONE VERSUS TREATMENT COMBINED WITH IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY IN PATIENTS OVER 75 YEARS
Authors: Marcelino Cortes, Juan Antonio Franco Pelaez, Marta Lopez Castillo, Alvaro Garcia Ropero, Maria Luisa Martin Mariscal, Angelica Maria Romero Daza, Julia Anna Palfy, Sem Briongos-Figuero, Mikel Taibo Urquia, Juan Benezet-Mazuecos, Jose Rubio Campal, Jeronimo Farre
Journal: Journal of the American College of Cardiology (2017)
TYPE 2 MYOCARDIAL INFARCTION IN YOUNG PATIENTS PORTENDS A WORSE LONG-TERM SURVIVAL
Authors: Avinainder Singh, Bradley Collins, Arman Qamar, Sanjay Divakaran, Josh Klein, Jon Hainer, Petr Jarolim, Ravi Shah, Marcelo Di Carli, Khurram Nasir, Deepak Bhatt, Ron Blankstein
Journal: Journal of the American College of Cardiology (2017)
Chemotherapy-induced diarrhea in older patients with colorectal cancer receiving fluoropyrimidines: A retrospective review.
Authors: Laxmi H Iyer, Ilene S. Browner, Amanda L. Blackford, Daniel A. Laheru, Nilofer Saba Azad, Luis A. Diaz, Ross C. Donehower, Michael J. Purtell, Lei Zheng, Dung T. Le, David Cosgrove, Zeshaan Rasheed, Maura Kadan, Ana De Jesus-Acosta
Journal: Journal of Clinical Oncology (2013)

e14647 Background: Chemotherapy-induced diarrhea (CID) is a common treatment-limiting toxicity of regimens used for colorectal cancer (CRC). Fluoropyrimidines, the backbone of CRC regimens, are associated with diarrhea, but the frequency and severity in older patients are less known due to under-representation of older patients in CRC trials. As life expectancy increases, the prevalence of older CRC patients will increase. We aimed to evaluate if older patients are vulnerable to CID. Methods: We retrospectively studied patients &gt;70 years old who received fluoropyrimidines based therapy for stages II-IV CRC at Johns Hopkins and Bayview Medical Center from 1996-2007. Patient demographics and cancer-specific data were retrieved. Diarrhea was graded per National Cancer Institute Clinical Toxicity Criteria. Results: We included 150 patients &gt; 70 years old. Median age was 75 (range 70-87). 65 (43%) were 70-74 years old, 52 (35%) were 75-79 years and 33 (22%) &gt; 80. Diarrhea occurred in 48% (n=72) of patients. Presence of diarrhea was not significantly associated with increasing age (70-74, 75-79 or &gt;80 years), gender, ECOG performance, number of comorbidities or medications. Severe grade 3-4 diarrhea occurred in 16% (n=24) and was associated with advanced stage (p=0.04). CID (all grades) was more common in cycle 1 than subsequent cycles (p=0.002). Conclusions: Fluoropyrimidines based therapy was tolerated in older patients with CRC. Incidence of CID was not associated with increasing age, gender, performance, comorbidities or polypharmacy. Severe diarrhea occurs in advanced stage and early during therapy. Larger prospective studies are needed to definitively evaluate the impact of age on CID.
Circulating DNA as a strong multimarker prognostic tool in metastatic colorectal cancer patients.
Authors: Safia El Messaoudi, Florent Mouliere, Caroline Mollevi, Brigitte Gillet, Michelle Nouaille, Virginie Loriot, Denis Pezet, Muriel Mathonnet, Marc Ychou, Alain Roger Thierry
Journal: Journal of Clinical Oncology (2014)

3604 Background: The aim of our study was to evaluate the prognostic role of various circulating cell-free DNA (cfDNA) parameters in metastatic colorectal cancer (mCRC) patients. Methods: We used a novel method, termed Intplex, which determines simultaneously from plasma, total cfDNA concentration, cfDNA fragmentation level, KRAS/BRAF mutational status, and cfDNA mutation load (% of mutant cfDNA). These parameters were tested in a mCRC patient cohort (n=98), which enabled validation of plasma DNA as a liquid biopsy to detect KRAS/BRAF mutations using the STARD criteria . Results: Median overall survival (OS) of the patients of the full cohort was 22 months (IC 95% [16.9-28.1]). Data confirmed BRAF mutational status as an excellent factor of poor prognosis (median OS, 22.9 vs. 3.4 months; relative risk (RR)=8.9, (IC95% [3.1-25.4], P<0.001) compared to KRAS mutational status (RR=1.1, IC 95% [0.7-1.9], P=0.66). OS was statistically different in patient groups with lower total cfDNA concentrations (median=28.1 months) compared with those with higher total cfDNA concentrations (median=17.8 months) than the median (RR=1.94, IC 95% [1.2-3.2], P=0.009). By using the multivariate Cox model, total cfDNA conc. proved statistically to be a strong, independent prognostic factor (P=0.035). Median OS was 31.1 and 11.1 months (P=0.121; RR=1.8, IC 95% [0.9-3.8]) in patients with lower and higher mutation loads than the median (10.3%). This difference was confirmed statistically when considering the mutant cfDNA conc. median (i.e. 3.1 ng/ml, RR=2.4, P=0.015). The fragmentation level did not appear to discriminate patients with regards to survival. CEA level at the conventional threshold conc. (5 ng/ml) was as a moderate prognostic factor (OS, 27.1 vs. 21.8 months; RR=1.24, 95% IC [0.7-2.2], P=0.48). Conclusions: Our study demonstrates for the time in a large cohort of mCRC patients that in addition to providing an advantageous alternative to tumor-tissue analysis for point mutation detection, other cfDNA parameters, such as total conc. and mutation load, are strong prognostic factors. Thus, prospective studies are needed to confirm multi-marker cfDNA analysis as a simple tool to help define the best care management options.
LONG TERM CLINICAL OUTCOMES AFTER ENDOVASCULAR RECANALIZATION IN PATIENTS WITH CHRONIC CAROTID ARTERY OCCLUSION
Authors: Mao-Shin Lin, Chi-Sheng Hung, Chih-Fan Yeh, Ching-Chang Huang, Ying-Hsien Chen, Hsien-Li Kao
Journal: Journal of the American College of Cardiology (2017)
Noninvasive Imaging in Adult Congenital Heart Disease
Authors: Luke J. Burchill, Jennifer Huang, Justin T. Tretter, Abigail M. Khan, Andrew M. Crean, Gruschen R. Veldtman, Sanjiv Kaul, Craig S. Broberg
Journal: Circulation Research (2017)

Multimodality cardiovascular imaging plays a central role in caring for patients with congenital heart disease (CHD). CHD clinicians and scientists are interested not only in cardiac morphology but also in the maladaptive ventricular responses and extracellular changes predisposing to adverse outcomes in this population. Expertise in the applications, strengths, and pitfalls of these cardiovascular imaging techniques as they relate to CHD is essential. The purpose of this article is to provide an overview of cardiovascular imaging in CHD. We focus on the role of 3 widely used noninvasive imaging techniques in CHD-echocardiography, cardiac magnetic resonance imaging, and cardiac computed tomography. Consideration is given to the common goals of cardiac imaging in CHD, including assessment of structural and residual heart disease before and after surgery, quantification of ventricular volume and function, stress imaging, shunt quantification, and tissue characterization. Extracardiac imaging is highlighted as an increasingly important aspect of CHD care.